Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
12 mars 2021 09h04 HE
|
Neos Therapeutics, Inc.
– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – –...
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
10 mars 2021 16h01 HE
|
Neos Therapeutics, Inc.
– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – –...
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
10 févr. 2021 08h00 HE
|
Neos Therapeutics, Inc.
– Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE,...
Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference
04 janv. 2021 16h01 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company
10 déc. 2020 08h00 HE
|
Neos Therapeutics, Inc.; Aytu BioScience
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s...
Neos Therapeutics Reports Third Quarter 2020 Financial Results
09 nov. 2020 07h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020
02 nov. 2020 08h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics to Present at Cantor Virtual Global Healthcare Conference
09 sept. 2020 08h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics Reports Second Quarter 2020 Financial Results
10 août 2020 07h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics to Host Second Quarter 2020 Financial and Operating Results Conference Call on August 10th, 2020
03 août 2020 08h00 HE
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...